News Finding: "In obese patients with T2DM requiring insulin therapy, we suggest adding at least one of the following: metformin, pramlintide (Symlin), or GLP-1 (glucagonlike peptide-1 receptor) agonists to mitigate associated weight gain due to insulin," they noted.
Paper Finding: (|QQQE) 2.2 In obese patients with T2DM requiring insulin therapy, we suggest adding at least one of the following: metformin, pramlintide, or GLP- agonists to mitigate associated weight gain due to insulin.
News Context: In a recommendation based on moderate quality evidence, the task force suggests that patients with diabetes who are obese or overweight should be given medications that promote weight loss or have no effect on weight as first-and second-line treatments. "In obese patients with T2DM requiring insulin therapy, we suggest adding at least one of the following: metformin, pramlintide (Symlin), or GLP-1 (glucagonlike peptide-1 receptor) agonists to mitigate associated weight gain due to insulin," they noted. Furthermore, the task force advises that ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers should be used as a first-line treatment for high blood pressure in obese people with type 2 diabetes.
Paper Context: Clinicians should discuss possible weight effects of glucose-lowering medications with patients and consider the use of antihyperglycemic medications that are weight neutral or promote weight loss. (|QQQE) 2.2 In obese patients with T2DM requiring insulin therapy, we suggest adding at least one of the following: metformin, pramlintide, or GLP- agonists to mitigate associated weight gain due to insulin. The first-line insulin for this type of patient should be basal insulin.